L antigen family member 1 peptide–HLA-A*02:01 complex (LAGE-1/HLA-A*02:01 complex)

The L antigen family member 1 peptide–HLA-A*02:01 complex (commonly called the NY-ESO-1/HLA-A*02:01 complex) consists of a tumor-associated antigenic peptide (such as NY-ESO-1 or LAGE-1) presented by the human major histocompatibility complex class I molecule HLA-A*02:01. This molecular complex acts as a ligand for T cell receptors and is a key target for immunotherapeutic approaches, including adoptive T cell transfer and TCR-mimetic biologic drugs, particularly in cancers where the NY-ESO-1 or LAGE-1 antigens are expressed[5][6]. Structural studies show that the peptide binds within the HLA-A*02:01 groove and forms a stable complex recognized by CD8+ T cells, facilitating the immune response against tumor cells expressing the target antigen[4]. The specificity and safety of therapeutics targeting this complex require careful validation due to potential cross-reactivity with similar peptides or HLA molecules[5][6].

Other names

NY-ESO-1 peptide–HLA-A*02:01 complexpMHC class I (peptide major histocompatibility complex I) complexHLA-A2/NY-ESO-1 complex

Immune activation: Drugs and biologics target the peptide–HLA-A*02:01 complex to engage T cells for tumor destruction. Cell recognition/inhibition: Used in bi-specific drug platforms and engineered T cell products for selectively attacking cancer cells expressing LAGE-1/NY-ESO-1 peptides. Safety switch: HLA-A*02:01 peptides can be used in safety mechanisms that prevent damage to healthy tissues.